Financial News
Articles published by Natera, Inc.
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
May 03, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
May 01, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Participate in March Investor Conferences
February 29, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
February 20, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
New Study Validates Signatera™ in Endometrial Cancer
February 05, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Acquires Reproductive Health Assets from Invitae
January 22, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.